Literature DB >> 19047166

ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway.

Ahmed Hamaï1, Franck Meslin, Houssem Benlalam, Abdelali Jalil, Maryam Mehrpour, Florence Faure, Yann Lecluse, Philipe Vielh, Marie-Françoise Avril, Caroline Robert, Salem Chouaib.   

Abstract

Human primary melanoma cells (T1) were found to be more susceptible to lysis by a Melan-A/MART-1-specific CTL clone (LT12) than their metastatic derivative (G1). We show that this differential susceptibility does not involve antigen presentation by target cells, synapse formation between the metastatic target and CTL clone, or subsequent granzyme B (GrB) polarization. Although PI-9, an inhibitor of GrB, was found to be overexpressed in metastatic G1 cells, knockdown of the PI-9 gene did not result in the attenuation of G1 resistance to CTL-induced killing. Interestingly, we show that whereas T1 cells express high levels of intercellular adhesion molecule-1 (ICAM-1), a dramatically reduced expression was noted on G1 cells. We also showed that sorted ICAM-1+ G1 cells were highly sensitive to CTL-induced lysis compared with ICAM-1- G1 cells. Furthermore, incubation of metastatic G1 cells with IFN-gamma resulted in the induction of ICAM-1 and the potentiation of their susceptibility to lysis by LT12. More importantly, we found that the level of ICAM-1 expression by melanoma cells correlated with decreased PTEN activity. ICAM-1 knockdown in T1 cells resulted in increased phosphorylation of PTEN and the subsequent activation of AKT. We have additionally shown that inhibition of the phosphatidylinositol (3,4,5)-triphosphate kinase (PI3K)/AKT pathway by the specific inhibitor wortmannin induced a significant potentiation of susceptibility of G1 and ICAM-1 small interfering RNA-treated T1 cells to CTL-induced lysis. The present study shows that a shift in ICAM-1 expression, which was associated with an activation of the PI3K/AKT pathway, can be used by metastatic melanoma cells to escape CTL-mediated killing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047166     DOI: 10.1158/0008-5472.CAN-08-0719

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Inhibition of cell proliferation by CD44: Akt is inactivated and EGR-1 is down-regulated.

Authors:  L-S Zhang; H-W Ma; H J Greyner; W Zuo; M E Mummert
Journal:  Cell Prolif       Date:  2010-08       Impact factor: 6.831

2.  Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Authors:  Ali R Jazirehi; James S Economou
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

3.  A quantitative method for screening and identifying molecular targets for nanomedicine.

Authors:  Peng Guo; Jiang Yang; Diane R Bielenberg; Deborah Dillon; David Zurakowski; Marsha A Moses; Debra T Auguste
Journal:  J Control Release       Date:  2017-03-22       Impact factor: 9.776

4.  Inducible RasGEF1B circular RNA is a positive regulator of ICAM-1 in the TLR4/LPS pathway.

Authors:  Wei Lun Ng; Georgi K Marinov; Ee Shan Liau; Yi Lyn Lam; Yat-Yuen Lim; Chee-Kwee Ea
Journal:  RNA Biol       Date:  2016-06-30       Impact factor: 4.652

5.  High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis.

Authors:  Dimitrios Mougiakakos; Riki Okita; Takashi Ando; Christoph Dürr; Jules Gadiot; Jiro Ichikawa; Robert Zeiser; Christian Blank; C Christian Johansson; Rolf Kiessling
Journal:  J Mol Med (Berl)       Date:  2012-01-17       Impact factor: 4.599

6.  Development and characterization of CD54-targeted immunoPET imaging in solid tumors.

Authors:  Weijun Wei; Dawei Jiang; Hye Jin Lee; Miao Li; Christopher J Kutyreff; Jonathan W Engle; Jianjun Liu; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-11       Impact factor: 9.236

7.  Polymorphisms of ICAM-1 are associated with gastric cancer risk and prognosis.

Authors:  Meng-Meng Tian; Yu Sun; Zhong-Wu Li; Ying Wu; Ai-Lian Zhao; Ji-You Li
Journal:  World J Gastroenterol       Date:  2012-01-28       Impact factor: 5.742

8.  Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced acute lung injury.

Authors:  Julia Svedova; Antoine Ménoret; Payal Mittal; Joseph M Ryan; James A Buturla; Anthony T Vella
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-04       Impact factor: 5.464

9.  Differences in sensitivity to tumor-specific CTLs between primary and metastatic esophageal cancer cell lines derived from the same patient.

Authors:  Yoshinobu Ichiki; Takeshi Hanagiri; Mitsuhiro Takenoyama; Tetsuro Baba; Yoshika Nagata; Makiko Mizukami; Tetsuya So; Masakazu Sugaya; Manabu Yasuda; Hidetaka Uramoro; Kosei Yasumoto
Journal:  Surg Today       Date:  2012-01-12       Impact factor: 2.549

10.  Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues.

Authors:  Sarah H Hayes; Gail M Seigel
Journal:  Int J Clin Exp Pathol       Date:  2009-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.